aliquot raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
The MTHFR nucleotide at position 677 in the gene has two possibilities: C (cytosine) or T (thymine). C at position 677 (leading to an alanine at amino acid 222) is the reference allele. The 677T allele (leading to a valine substitution at amino acid 222) encodes a thermolabile alternative enzyme variant with reduced activity. Both reference and alternative genotypes are common, with the alternative allele frequency at 10-35%, depending on ancestry. Individuals with two copies of 677C (677CC) have the most common genotype. 677TT individuals (homozygous) have lower MTHFR activity than CC or CT (heterozygous) individuals. About ten percent of the North American population are T-homozygous for this polymorphism. There is ethnic variability in the frequency of the T allele – frequency in Mediterranean/Hispanics is greater than the frequency in Caucasians which, in turn, is greater than in Africans/African-Americans. The degree of enzyme thermolability (assessed as residual activity after heat inactivation) is much greater in 677TT individuals (18–22%) compared with 677CT (56%) and 677CC (66–67%). Individuals of 677TT are predisposed to mild hyperhomocysteinemia (high blood homocysteine levels), because they have less active MTHFR available to produce 5-methyltetrahydrofolate (which is used to decrease homocysteine). Low dietary intake of the vitamin folate can also cause mild hyperhomocysteinemia. Low folate intake affects individuals with the 677TT genotype to a greater extent than those with the 677CC/CT genotypes.
==== Cardiovascular tissues ==== Cardiovascular regenerative medicine focuses on repairing damaged myocardial tissue, heart valves, and peripheral blood vessels, primarily targeting ischemic heart disease and congenital heart defects. Because adult mammalian cardiomyocytes possess highly restricted proliferative capacity, therapeutic strategies utilize engineered cardiac patches, cell-seeded hydrogels, and decellularized extracellular matrix (ECM) components to stimulate localized myocardial repair after a myocardial infarction. Clinical and pre-clinical research focuses heavily on using induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and vascular endothelial cells embedded within porous, biomimetic polymeric scaffolds to ensure functional electrical coupling and host tissue integration. Additionally, tissue-engineered vascular grafts (TEVGs) are investigated as synthetic or bio-resorbable alternatives for coronary artery bypass surgery, where scaffold porosity is precisely tuned to allow host cell infiltration, smooth muscle cell remodeling, and functional neovascularization without inducing thrombosis.
The Bard Gorlen series "Catamounts" (September 1996, The Magazine of Fantasy and Science Fiction) "Childrun" (August 2008, The Magazine of Fantasy and Science Fiction) "Quickstone" (March 2009, The Magazine of Fantasy and Science Fiction) "Bemused" (September/October 2013, The Magazine of Fantasy and Science Fiction) "Rooksnight" (May/June 2014, The Magazine of Fantasy and Science Fiction) "Catamounts" (Reprint) (August 2013, Lightspeed) "Belweather" (September 2013, Lightspeed) "Stillborne" (November/December 2017, The Magazine of Fantasy and Science Fiction) "Weeper" (September/October 2020, The Magazine of Fantasy and Science Fiction) "Underneath the Oversea" (November 2020)
== Discovery == In 1839, the German anatomist Hermann Friedrich Stannius discovered a pair of novel structures inside the kidneys of sturgeon and bony fishes. He believed that they were a kind of adrenal gland (found in mammals) in these fishes. In 1896, the French physiologist A. Petit demonstrated that removal of one of the structures led to degeneration of the other. He suggested that these structures were endocrine organs. In 1908, the Italian zoologist Ercole Giacomini was the first to describe that these structures were present only in fishes which lack a parathyroid gland. He distinguished and named them "posterior interrenal" from the anterior portion of the kidney, which he named "anterior interrenal". A French Physiologist M. Fontaine reported that the corpuscles were responsible for controlling calcium level in the blood. In 1971 Peter K.T. Pang of Yale University showed in the male killifish, Fundulus heteroclitus, that the corpuscles control calcium metabolism. He found that removal of the corpuscle led to development of kidney stone and increase in serum calcium level. By the mid 1970s, it was confirmed that the corpuscles secrete a factor that can reduce calcium level, similar to calcitonin but completely different. and Pang gave the prospective name "hypocalcin". The chemical compound was isolated in 1986 from sockeye salmon (Oncorhynchus nerka), and since it was from a teleost, it was called "teleocalcin". A better isolation was reported in 1988 from different species, including European eel, tilapia, goldfish, and carp.
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
Sources: en.wikipedia.org
===== Light collector ===== Using graphene as a photoactive material requires its bandgap to be 1.4–1.9 eV. In 2010, single cell efficiencies of nanostructured graphene-based PVs of over 12% were achieved. According to P. Mukhopadhyay and R. K. Gupta organic photovoltaics could be "devices in which semiconducting graphene is used as the photoactive material and metallic graphene is used as the conductive electrodes". In 2008, chemical vapor deposition produced graphene sheets by depositing a graphene film made from methane gas on a nickel plate. A protective layer of thermoplastic is laid over the graphene layer and the nickel underneath is then dissolved in an acid bath. The final step is to attach the plastic-coated graphene to a flexible polymer sheet, which can then be incorporated into a PV cell. Graphene/polymer sheets range in size up to 150 square centimeters and can be used to create dense arrays. Silicon generates only one current-driving electron for each photon it absorbs, while graphene can produce multiple electrons. Solar cells made with graphene could offer 60% conversion efficiency.
=== Viscoelasticity === For hydrogels, their elasticity comes from the solid polymer matrix while the viscosity originates from the polymer network mobility and the water and other components that make up the aqueous phase. Viscoelastic properties of a hydrogel is highly dependent on the nature of the applied mechanical motion. Thus, the time dependence of these applied forces is extremely important for evaluating the viscoelasticity of the material. Physical models for viscoelasticity attempt to capture the elastic and viscous material properties of a material. In an elastic material, the stress is proportional to the strain while in a viscous material, the stress is proportional to the strain rate. The Maxwell model is one developed mathematical model for linear viscoelastic response. In this model, viscoelasticity is modeled analogous to an electrical circuit with a Hookean spring, that represents the Young's modulus, and a Newtonian dashpot that represents the viscosity. A material that exhibit properties described in this model is a Maxwell material. Another physical model used is called the Kelvin-Voigt Model and a material that follow this model is called a Kelvin–Voigt material. In order to describe the time-dependent creep and stress-relaxation behavior of hydrogel, a variety of physical lumped parameter models can be used. These modeling methods vary greatly and are extremely complex, so the empirical Prony Series description is commonly used to describe the viscoelastic behavior in hydrogels.
A skeleton is the structural frame that supports the body of most animals. There are several types of skeletons, including the exoskeleton, which is a rigid outer shell that holds up an organism's shape; the endoskeleton, a rigid internal frame to which the organs and soft tissues attach; and the hydroskeleton, a flexible internal structure supported by the hydrostatic pressure of body fluids. Vertebrates are animals with an endoskeleton centered around an axial vertebral column, and their skeletons are typically composed of bones and cartilages. Invertebrates are other animals that lack a vertebral column, and their skeletons vary, including hard-shelled exoskeleton (arthropods and most molluscs), plated internal shells (e.g. cuttlebones in some cephalopods) or rods (e.g. ossicles in echinoderms), hydrostatically supported body cavities (most), and spicules (sponges). Cartilage is a rigid connective tissue that is found in the skeletal systems of vertebrates and invertebrates.
== Computational analysis == The mass spectrometric analysis produces a list of molecular weights which is often called a peak list. The peptide masses are compared to protein databases such as Swissprot, which contain protein sequence information. Software performs in silico digests on proteins in the database with the same enzyme (e.g. trypsin) used in the chemical cleavage reaction. The mass of these peptides is then calculated and compared to the peak list of measured masses. The results are statistically analyzed and possible matches are returned in a results table.
Sources: en.wikipedia.org
=== Bioethics === As additional tests are discussed for addition to the panels, issues arise. Many question whether the expanded testing still falls under the requirements necessary to justify the additional tests. Many of the new diseases being tested for are rare and have no known treatment, while some of the diseases need not be treated until later in life. This raises more issues, such as: if there is no available treatment for the disease should we test for it at all? And if we do, what do we tell the families of those with children bearing one of the untreatable diseases? Studies show that the rarer the disease is and the more diseases being tested for, the more likely the tests are to produce false-positives. This is an issue because the newborn period is a crucial time for the parents to bond with the child, and it has been noted that ten percent of parents whose children were diagnosed with a false-positive still worried that their child was fragile and/or sickly even though they were not, potentially preventing the parent-child bond forming as it would have otherwise. As a result, some parents may begin to opt out of having their newborns screened. Many parents are also concerned about what happens with their infant's blood samples after screening.
The horticulture industry embraces the production, processing and shipping of and the market for fruits and vegetables. As such it is a sector of agribusiness and industrialized agriculture. Industrialized horticulture sometimes also includes the floriculture industry and production and trade of ornamental plants. Among the most important fruits are:
==== Almond tofu ==== "Almond tofu" (Chinese: 杏仁豆腐 xìngrén dòufu; Japanese: annindōfu) is a milky white and gelatinous substance resembling tofu, but it does not use soy products or soy milk and is hardened with agar. A similar dessert made with coconut milk or mango juices may occasionally be referred to as "coconut tofu" or "mango tofu", although such names are also given to hot dishes that use soy tofu and coconut or mango in the recipe.
2016 It was found that the replenishment of NAD+ in the organism of mice through precursor molecules improves the functioning of mitochondria and stem cells, and also leads to an increase in their lifespan. One of these NAD+ precursor molecules is NMN. 2016 Demonstration that a combination of longevity associated drugs can additively extend lifespan, at least in mice. 2016 As part of the implementation of the SENS programs, researchers managed to make two mitochondrial genes, ATP8 and ATP6, stably express from the cell nucleus in the cell culture. 2016 Scientists show that expressing Yamanaka reprogramming factors in mice with premature aging can extend their lifespan by about 20%. 2017 The discovery that a naturally occurring polymorphism in human signaling pathways is in some cases associated with health and longevity. It was also detected that, the same as in mice, this association can depend on the sex (it can be observed for one sex but not for another). This indicates that by correctly influencing these pathways, it is theoretically possible to alter lifespan and healthspan in humans. 2017 AgeX Therapeutics, a biotechnology company focused on medical therapeutics related to longevity, was founded. 2018 The Nobel Prize for cancer research was awarded to James Allison and Tasuku Honjo. (The main cause of cancer is the accumulation of errors in DNA.
Hong Kong is a special administrative region of China, with executive, legislative, and judicial powers devolved from the national government. The Sino-British Joint Declaration provided for economic and administrative continuity through the handover, resulting in an executive-led governing system largely inherited from the territory's history as a British colony. Under these terms and the "one country, two systems" principle, the Basic Law of Hong Kong is the regional constitution. The regional government is composed of three branches:
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Dry powder is normally held at -20 °C or lower, away from light and moisture. Sealed vials can also be kept at 2-8 °C for shorter intervals. Warming to room temperature before opening prevents condensation.